PROTACs
-
22:23
Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift
Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the cl
-
16:42
How to keep your degrader pipeline moving forward with Dianthus
The development of your protein degrader is a multi-step and complex process usually packed with challenges that if left unsolved will delay the progress of your project. What if you could overcome co
-
Top 8 targeted protein degradation conferences of 2023 at a glance
Use this downloadable list of 2023 Targeted Protein Degradation conferences to choose which one(s) to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.
-
8 Targeted Protein Degradation conferences in 2023 you won’t want to miss
2023 is expected to be a year of big announcements in the targeted protein degradation (TPD) therapeutics space. With more than 20 degraders in clinical trials, many decisions are coming. The...
-
How to build an effective protein degrader
-
37:25
Put your challenging affinity screening campaigns back on track — after you’ve tried everything else
When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
-
59:35
How to improve the function of your PROTAC degrader by understanding ternary complex formation
Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target
-
Why so many companies are betting on PROTACs as a superior therapeutic modality
One advantage of PROTACs is their unique mode of action — the induced proximity of an E3 ligase and the protein of interest (POI) triggers the ubiquitination and then degradation of the POI by...
-
Trying to characterize ternary complex formation and cooperativity?
Find out more
In-solution measurements will help -
Rely on Dianthus to overcome roadblocks in your PROTAC characterizations
-
Discover tools to successfully characterize PROTAC binary and ternary complexes
Read more -
Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust
-
35:47
Improve your protein degrader design with new ways to discover E3 ligase ligands
Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
-
10 terms to help you more easily understand targeted protein degradation
If you’re new to the world of TPD or you’re trying to keep up with all developments in this fast-moving field, here are some terms and definitions that will help you. The post 10 terms to help...
-
Protein degraders show promising results in drug development pipelines. See progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...
-
9 Targeted Protein Degradation conferences you don’t want to miss in 2022
With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...
-
For protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome
The total protein degradation modality — locally and specifically targeting the disease-causing proteins and degrading their toxic aggregates — promises to be revolutionary. But the development...
-
Targeted protein degradation promises to lead the way to effective drugs for challenging targets
-
MST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development
-
Ddi1 is a ubiquitin-dependent protease
-
Trying to characterize ternary complex formation and cooperativity?
Find out more
In-solution measurements will help -
Are you building an effective protein degrader? 4 questions to ask yourself to find out
Protein degraders are getting a lot of attention for being a new and promising modality to treat diseases such as cancer or Alzheimer’s disease. Rather than inhibiting the function of a protein,...
-
Discover tools to successfully characterize PROTAC binary and ternary complexes
Read more -
6 protein degradation conferences in 2021 you can’t afford to miss
Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the emerging field of targeted protein degradation (TPD). The post 6 protein degradation conferences in...
-
Loading more...